» Articles » PMID: 31928014

Liposome Imaging in Optically Cleared Tissues

Overview
Journal Nano Lett
Specialty Biotechnology
Date 2020 Jan 14
PMID 31928014
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Three-dimensional (3D) optical microscopy can be used to understand and improve the delivery of nanomedicine. However, this approach cannot be performed for analyzing liposomes in tissues because the processing step to make tissues transparent for imaging typically removes the lipids. Here, we developed a tag, termed REMNANT, that enables 3D imaging of organic materials in biological tissues. We demonstrated the utility of this tag for the 3D mapping of liposomes in intact tissues. We also showed that the tag is able to monitor the release of entrapped therapeutic agents. We found that liposomes release their cargo >100-fold faster in tissues than in conventional assays. This allowed us to design a liposomal formulation with enhanced ability to kill tumor associated macrophages. Our development opens up new opportunities for studying the chemical properties and pharmacodynamics of administered organic materials in an intact biological environment. This approach provides insight into the behavior of degradable materials, where the newly discovered information can guide the engineering of the next generation of imaging and therapeutic agents.

Citing Articles

Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning.

Luo J, Molbay M, Chen Y, Horvath I, Kadletz K, Kick B Nat Biotechnol. 2025; .

PMID: 39809933 DOI: 10.1038/s41587-024-02528-1.


Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances.

Zhu C, Mu J, Liang L J Nanobiotechnology. 2024; 22(1):688.

PMID: 39523313 PMC: 11552240. DOI: 10.1186/s12951-024-02969-5.


Nanotechnology in retinal diseases: From disease diagnosis to therapeutic applications.

Kaur G, Bisen S, Singh N Biophys Rev (Melville). 2024; 5(4):041305.

PMID: 39512331 PMC: 11540445. DOI: 10.1063/5.0214899.


Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy.

Patel Y, Manturthi S, Tiwari S, Gahunia E, Courtemanche A, Gandelman M ACS Pharmacol Transl Sci. 2024; 7(10):3086-3095.

PMID: 39416959 PMC: 11475319. DOI: 10.1021/acsptsci.4c00292.


Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles.

Wang L, Quine S, Frickenstein A, Lee M, Yang W, Sheth V Adv Funct Mater. 2024; 34(8).

PMID: 38828467 PMC: 11142462. DOI: 10.1002/adfm.202308446.